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ABSTRACT 
 
We report a new technique, surface inhibited nucleation, to achieve control over the 
selective growth of pharmaceutical polymorphs. It is widely known that fluorous 
substrates such as Teflon exhibit favorable intermolecular interactions with other fluorous 
entities but disfavorable interactions with hydrophilic as well as oleophilic entities. In this 
work we show that the supramolecular xenophobia exhibited by fluorous surfaces can be 
used as a tool to inhibit crystal nucleation and growth. We describe the unique ability of 
perfluoroalkyl terminated silane monolayers in promoting the exclusive growth of the 
stable polymorph (g-form) of indomethacin, a non-steroidal anti-inflammatory drug 
(NSAID). This selective growth is promoted not by the enhanced nucleation of the g-
form, but by the suppressed nucleation of the metastable polymorph (a-form). This 
suppression is due to the disfavored interactions between the non-fluorous faces of the 
crystal nuclei and fluorous walls of the vial. This selectivity can be reversed by using a 
drug for which the crystal faces are bounded by fluorous surfaces. Thus, crystallization of 
flufenamic acid (an NSAID) in fluorous vials yields the growth of metastable polymorph, 
but crystals of stable polymorph are grown in vials exposing hydroxy groups. Unlike the 
surface enabled crystal growth methodologies developed before, the current technique 
does not require the knowledge of specific interfacial interactions. Thus, this new method 
can be applied to any solid drug even if it’s structural, morphological and other physical 
properties are unknown. We expect that the use of this method will significantly increase 
the probability of finding the thermodynamically stable drug polymorphs at the early 
stages of pharmaceutical development. 
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INTRODUCTION 
 
Polymorphism, the ability of a chemical entity (organic molecule, ion pair, polypeptide) 
to exist in multiple crystal structures, is a fundamental solid state property that affects a 
variety of industries especially the pharmaceutical industry.
1
  Different polymorphs of the 
same compound often exhibit very different properties that can affect a drug’s potency in 
the body.
2
  Dissolution rate, solubility, chemical stability, and tabletability can vary 
widely between different polymorphic forms.
3
  In addition to differences in their 
properties, different polymorphs can be patented separately, so the discovery of a new 
polymorph has important implications for protection of intellectual property.  The 
importance of polymorphism in the pharmaceutical industry and public health is 
illustrated by ritonavir, a protease inhibitor drug manufactured by Abbott
4
.  Two years 
after the launch of this drug, a new polymorph that is more stable began to crystallize, 
rendering this life-saving drug six times less soluble
56
.  Ritonavir had to be pulled from 
the market, which cost millions of dollars and human suffering.  It was reformulated 
later, and re-released in a liquid formulation.  Instances like this show the need for 
intense screening for different polymorphs of a drug before it is released into the market.    
 
In this report, we will detail our methods for selective polymorph growth through glass 
slides and vials with their surface properties altered to promote or inhibit nucleation of 
certain polymorphs.  We will explain the benefits of our new method of forming self 
assembled monolayers on the inside of glass vials.  Using these monolayer surfaces, we 
show the selective nucleation and crystal growth of indomethacin, flufenamic acid, and 
 2 
nitrofurantoin.  We will also detail why fluorous surfaces are important in promoting 
thermodynamically stable polymorphs. 
 
BACKGROUND 
 
The first distinction of different polymorphic forms occurs at nucleation.  Theoretically, 
if one can control the nucleation of crystals, it is possible to grow exclusively one 
polymorph from solution.   
Figure 1.  Surface and volume contribution to the potential energy of a growing crystal 
nuclei.  Initially the surface forces exceed volume forces; as the cluster grows the 
contributions from volume forces increases.  When the clusters reach a critical size the 
two forces are balanced; those clusters are termed crystal nuclei.  The growth of these 
critical clusters into larger clusters and crystals is referred to as nucleation.
7
 
 
For a crystal to nucleate, it must overcome the nucleation energy barrier (Figure 1).  For 
any cluster of molecules in solution, there are forces between the molecules holding them 
together (volume forces), as well as forces from the solvent pulling them apart (surface 
forces).  Nucleating crystals become stable and keep growing when the volume 
contributions outweigh the surface contributions.  The polymorphic form that a crystal 
takes at the point where it is large enough not to break apart from solvent interactions will 
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be a template for more molecules to add onto, and can seed the rest of the solution.  To 
lower the interaction between growing nuclei and the surroundings (e.g. solvent), and 
thus decrease the nucleation barrier, crystals usually nucleate on a surface, removing an 
entire face from solvent interaction.  Metastable or kinetically stable polymorphs will 
typically form first in solution because their nucleation barrier is lower than the 
thermodynamically stable form.  As metastable forms have weaker interactions within the 
crystals than thermodynamically stable forms, they are more easily broken apart by 
solvent interactions.
8
  Providing a nucleation surface to limit solvent interaction can 
promote the exclusive growth of a metastable form.  Similarly, providing a surface with 
favorable interactions such as hydrogen bonding with a metastable form can promote its 
exclusive growth.  Thermodynamically stable polymorphs can be favored by providing 
surfaces with favorable interactions.  As shown later in this paper, thermodynamically 
stable forms can also be favored by inhibiting nucleation on surfaces through 
disfavorable surface interactions with the metastable form.  This inhibition not only 
increases the nucleation barrier of the metastable form, but also allows for crystal 
nucleation below the solvent level, allowing Ostwald ripening to promote the growth of 
thermodynamically stable crystals at the expense of their metastable competitors. 
 
FORMATION OF FUNCTIONALIZED SURFACES 
 
Our early work on functionalized surfaces used glass slides coated with various self 
assembled silane monolayers.  Described below are the methods of preparing the 
monolayers on slides and in vials. 
 4 
Slide preparation 
 
Silane Monolayers on Glass Slides9 
Preparation of the slides involved first cutting the glass into small rectangles 
(approximately 1x2 cm) to fit inside vials containing the solution of the pharmaceutical.  
These cut slides were cleaned with piranha solution (70% sulfuric acid, 30% hydrogen 
peroxide) for at least 30 minutes, and then rinsed with DI water.  The clean slides were 
placed in a KOH solution to hydroxylate the surface for at least one hour.  The slides 
were again rinsed and dried with nitrogen gas.  A solution of fresh dilute trichlorosilane 
in dichloromethane (approx 1 drop trichlorosilane per 100 mL) was prepared.  The 
hydroxylated slides were immersed into the silane solutions for a minimum of two hours.  
Careful preparation and handling of this solution was necessary, as the trichlorosilanes 
readily reacted with water.  The slides were taken out of solution and rinsed with both 
dichloromethane and ethyl acetate.  If slides appeared cloudy, they were cleaned again 
with ethyl acetate until clear surfaces were obtained.  Figure 2 lists the trichlorosilanes 
used in this work.   
 
Silane Monolayers on Glass vials 
Glass vials of various sizes were filled with piranha solution and left for at least 30 
minutes.  The vials were rinsed with DI water several times before being filled with a 
KOH solution.  This solution was left in the vial for at least one hour, after which the 
slides were rinsed again.  The vials were dried with nitrogen gas to remove any moisture 
and then filled with a dilute dichloromethane solution of the desired trichlorosilane.  The 
vials were capped and allowed to sit for at least two hours.  The vials were then rinsed 
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with dichloromethane and ethyl acetate.  If they remained cloudy, vials were sonicated 
while filled with ethyl acetate until they were clear.  
 
For a more efficient and less hazardous preparation of functionalized glass vials, we 
substituted plasma oxidation for oxidation with piranha.  The glass vials were placed in 
the chamber of an SPI Plasma Prep II apparatus.  The vials were oxidized by oxygen 
plasma under vacuum for at least one minute.  They were then immediately removed and 
filled with a dilute dichloromethane solution of the desired trichlorosilane.  The vials 
were capped to prevent moisture from the atmosphere from contaminating the solution, 
and left for at least two hours.  The vials were rinsed with dichloromethane and ethyl 
acetate, and sonicated while filled with ethyl acetate to remove any cloudiness. 
 
 
Figure 2.  Structures of trichlorosilanes used in this work.  The image on the right 
shows the schematic structure of a silane monolayer.  The monolayer “7” leads to 
“perfluorinated” or “fluorous” surfaces.10,11,12 
 
 
 
 
 
1: R = -CH2CH2CO2CH3 
2: R = -CH2CH2CH2CN 
3: R = -CH2CH2CH2Cl 
4: R = -C6H4CH2Cl 
5: R = -(CH2)9CH=CH2 
6: R = -(CH2)17CH3 
7: R = -(CH2)2(CF)4CF3 
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METHODS OF CRYSTALLIZATION 
 
Crystallization on slides 
Solutions of desired pharmaceuticals were placed in vials containing glass slides in two 
configurations.  One method was to have the glass slide laying flat on the bottom of the 
vial as seen in Figure 3a.  The functionalized surface was facing upwards to allow 
interaction with the solvent.  Vials were filled with solution of the desired pharmaceutical 
to about 1/3 of the height of the vial.  Another method was to have the glass slide at an 
angle in the vial, with the functionalized surface facing upwards, as shown in Figure 3b.  
Formation of crystals on this surface should show some affinity of the solid to the surface 
to allow them to stick.  Vials were filled with solutions of pharmaceuticals to a point just 
above the top of the slide. 
 
 
 
 
Figure 3.  Crystal growth on functionalized glass slides that are laid flat (a) in inclined 
(b) from solutions placed in plain (unmodified) glass vials.  
 
 
Both of these methods were used for crystallizations of pharmaceutical compounds.  One 
issue we had to deal with was possible growth of crystals from solution and vial surfaces 
that did not expose the desired monolayer.  We observed crystal growth mainly at edges 
between the slide and the vial as opposed to desired crystal growth on the functionalized 
surface of the slide. 
  (a)                     ( b) 
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Crystallization in functionalized vials 
To eliminate undesired nucleation sites, the entire interior of a glass vial was 
functionalized with a particular monolayer.  This method forces nucleation to occur either 
on the desired surface or in solution.  We used vials with three different sizes in this 
work: ½ dram, 3 dram, and 20 mL.  Most work was done in ½ dram vials shown in 
Figure 4.  Vials were filled with the solution of a desired pharmaceutical compound to 
about 1/3
rd
  of the height of the vial used. 
 
   Figure 4.  Optical photograph of a ½ dram vial. 
 
Preparation of solutions 
All the solutions of pharmaceuticals that we prepared were either saturated or nearly 
saturated to enforce surface induced crystal growth.  The pharmaceutical compound was 
weighed out and placed in a flask containing the desired solvent.  The solution was 
sonicated until the drug was completely dissolved; it was then heated and stirred for at 
least 30 minutes to break apart any clusters present in solution.  In a given set of 
experiments, the same crystallization solution was used in vials with different 
functionalized surfaces to ensure consistency.  Vials were then capped with aluminum 
foil to prevent dust and other contaminants from getting into the vial and 4-5 holes were 
made in the foil to allow evaporation.  Vials were placed in various locations, but were 
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mainly contained to a hood to prevent atmospheric changes or accidental contact from 
affecting crystal growth. 
 
INDOMETHACIN 
 
Indomethacin is a drug used for the treatment of arthritis and gout; it falls into the 
category of NSAIDs (non-steroidal anti-inflammatory drugs).  This is an interesting drug 
because its two widely known polymorphs (  and ) crystallize concomitantly from 
solution at room temperature.
13
   
 
Figure 5. The structure of indomethacin.  Notice the carboxy, imido, chloro and 
methoxy functional groups. 
 
The  form of indomethacin is kinetically stable (metastable), and the  form is 
thermodynamically stable (stable).  Under normal conditions both forms grow 
concomitantly from ethanol solutions in glass vials and on glass slides.  Several glass 
slides were prepared with each of the monolayers listed in Figure 2.  Indomethacin was 
allowed to crystallize from ethanol at room temperature in a clean vial with these slides 
laying flat at the bottom of the vial.  It was observed that on every slide except for the 
perfluorinated slides, both forms were present.  On the perfluorinated slides only the  
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form was observed, even though the  form was growing at other points in the vial 
(predominantly on the walls).   
 
These experiments were repeated with glass vials functionalized with the same 
monolayers.  Again, it was observed in every vial except for those with the perfluoro 
surfaces both  and  forms were present, with the  form being predominant.  The vials 
coated with the perfluoro surface grew exclusively the  form.   Another interesting 
observation was that in all vials except for perfluorinated vials crystals were present on 
the walls.  Figures 7-11 show the optical images of the crystals, experimental powder X-
ray diffraction patterns and packing structures drawn from reported crystal 
structures.
14,15,16
 
 
Figure 6.  Microscope images of the stable () form of indomethacin on the left, and 
metastable () form on the right. 
 
 
2 (°)
5 15 25 35
  
Figure 7.  Powder X-ray diffraction pattern of the  (stable) form. 
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Figure 8.  Powder X-ray diffraction pattern of the  (metastable) form. 
 
 
 
 
 
Figure 6.  Crystal structure of the  (stable) form of indomethacin. 
 
 
 
Figure 7.  Crystal structure of the  (metastable) form of indomethacin. 
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The exclusive growth of the  form of indomethacin on perfluorinated surfaces, and the 
concomitant growth of both and  forms on every other surface led us to conclude that 
the fluorous surfaces play a critical role in the nucleation process.  Additionally, the 
form crystallized predominantly on the walls of vials coated with non-fluorous silane 
monolayers (1-6).  The walls of the vials coated with fluorous monolayers are “clean”, 
showing no affinity for crystal growth.  These observations led us to postulate that the 
perfluorinated surfaces suppress the growth of the  form by preventing the adhesion of 
nucleating crystals to the surface.  The suppression of surface induced nucleation allows 
more time for the thermodynamically stable  form to nucleate in the solution.  With 
time, the stable form continues to grow while the solvent is still present, at the expense of 
any metastable  crystals that may be present.  This phenomenon of the growth of a 
stable species at the expense of a metastable species is widely known as Ostwald 
ripening.
17
,
18
  This effect is not seen in vials containing other monolayers because these 
surfaces enable the attachment of crystal nuclei of form and their further growth into 
macroscopic crystals. 
 
FLUFENAMIC ACID 
 
Flufenamic acid is an NSAID that is used in the treatment of musculoskeletal and joint 
disorders.
19
  This drug was of particular interest to us because of its many polymorphic 
forms (two forms being stable at room temperature), its CF3 group, and the layered 
crystal structures of the two polymorphs.  
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Figure 8.  Structure of flufenamic acid.  Note the carboxy, secondary amino, and 
especially the trifluoro-methyl functional groups. 
 
One curious trait of flufenamic acid is the temperature dependence of polymorph 
stability.  Below 42 ºC, form III is the thermodynamically stable polymorph, and form I 
is the metastable polymorph.
20,21
  Above 42 ºC form I is the most thermodynamically 
stable, and form III becomes the metastable polymorph.  Above 104 ºC form II becomes 
more stable than form III.  The relationships between polymorph stability can be seen in 
Figure 12 below.
22
  Forms I and III are readily obtained through solvent evaporation; they 
are both stable at room temperature and enantiotropic to each other.
23
  Form II can be 
obtained from sublimation.  Single crystal X-ray diffraction data is available for forms I 
and III, while powder X-ray diffraction data is available for form II.   
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Figure 9.  Relative free energies of various polymorphs of flufenamic acid plotted as a 
function of temperature. Taken from reference 22. 
 
 
Flufenamic acid was studied by conducting crystallizations exclusively in glass vials.  
Our first attempts at detecting surface specific polymorphism used saturated solutions of 
flufenamic acid in ethanol.  Vials with several functionalized surfaces were filled with the 
same saturated solution.  Two of each clean glass, hydroxyl (plasma treated glass), 
carbomethoxy (2), undecenyl (5), and perfluoro (7) vials were filled about 1/3 of the way 
with the solution.  Vials were left in the hood until all solvent had evaporated.  All vials 
produced yellow crystals appearing as thin needles under microscope except for the 
perfluoro vials.  Crystals formed at the bottom of the perfluorinated vial were white and 
appeared more powdery than the yellow crystals seen in other vials.  A clump of yellow 
crystals was formed on top of this white powder, but was not in contact with the walls or 
the bottom of the vial.   The white powder was shown to be form I by powder X-ray 
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diffraction, and the yellow needles were shown to be form III also by powder diffraction.  
These results were very encouraging, and another experiment was set up.  This time, five 
vials with perfluorinated surfaces, and five with hydroxyl surfaces were filled with a 
fresh saturated solution of flufenamic acid.  These two surfaces were selected because 
they showed the greatest difference in solvent affinity (contact angles).  The vials were 
capped with aluminum foil and left in the same hood as the previous experiment until all 
solvent was evaporated.  The results of this were clear block shaped crystals in all of the 
perfluorinated vials, and yellow needles in all of the hydroxy vials that can be seen in 
Figures 13 and 14.  Crystals formed in the perfluorinated vials were confirmed to be form 
I by powder X-ray diffraction (Figure 15), and crystals from hydroxy vials were 
confirmed to be form III also by powder X-ray diffraction (Figure 16).  Contrary to every 
other drug crystallized in hydroxyl vials, the flufenamic acid did not stick to the sides but 
crystallized at the bottom, typically in a ring shape as shown in Figure 13.  
 
Figure 10. Crystal growth of flufenamic acid from the same bulk solutionin hydroxy 
and perfluoro vials.  Form III is the yellow form seen in the hydroxy vial (OH), form I 
can be seen in the perfluorinated vial (PF). A view from the bottom of the 
perfluorinated vial shows the block shaped crystals of form I. 
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Figure 11.  Microscopic images of form I grown in a perfluorinated vial (left), and 
form III grown in a hydroxy vial (right).  
 
 
 
 
Figure 12.  Powder X-ray diffraction pattern of form I.  The blue line is the 
experimental result from a perfluorinated vial; the magenta line is the diffraction pattern 
calculated from single crystal X-ray data. 
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Figure 13.  Powder X-ray diffraction pattern of form III.  The blue line is the 
experimental result from a hydroxy vial, and the magenta line is the diffraction pattern 
calculated from single crystal X-ray data. 
 
 
 
Figure 14.  Crystal structure of form I.  Notice the layered arrangement of molecules 
and exposure of CF3 groups at layers parallel to largest crystal faces.  Notice also the 
wave-like (trough and crest) pattern at the surface and the inter-digitation of CF3 
groups. 
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Figure 15. Crystal structure of form III.  Notice the layered structure with CF3 groups at 
the layer surface.  Contrast figures 17 and 18 to notice the absence of wave-like 
structure and inter-digitation of CF3 groups. 
 
 
Crystallizations of flufenamic acid in hydroxy and perfluorinated vials at room 
temperature were repeated several times, and the results were found to be consistently 
reproducible.  
 
The enantiotropic relationship between forms I and III was tested with differential 
scanning calorimetry (DSC), as seen in Figures 19 and 20.  Form I did not show a peak 
corresponding to a transition (Figure 20), confirming that it is the most stable polymorph 
at temperatures close to the melting point.  Form III shows a dip just below the melting 
point (Figure 19) that is not seen in form I indicating that it is transforming to some more 
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stable polymorph.  These results were found to be consistent for every sample tested with 
DSC. 
 
Figure 16.  DSC trace of form III grown in a hydroxy vial.  
 
 19 
Figure 17.  DSC trace of form I grown in from a perfluorinated vial. 
 
 
To expand on our research with flufenamic acid, several sets of hydroxy and 
perfluorinated vials were filled with a solution of flufenamic acid in ethanol and allowed 
to crystallize at several different temperatures.  All vials were filled with the same stock 
solution.  Vials left in the hood at room temperature grew form I in perfluorinated vials, 
and form III in the hydroxy vials.  Vials left in an oven set to approximately 42 ºC grew 
exclusively form III regardless of the SAM.  Vials left in an oven above 80 ºC grew 
exclusively form III.  To solve the problem of the solvent evaporating too quickly to 
allow the surface to have a significant effect, the experiments were repeated with 
solutions of flufenamic acid in toluene.  Vials left at room temperature grew exclusively 
form I regardless of SAM.  Vials left at approximately 42 ºC were also exclusively form I 
regardless of SAM.  Vials left above 80 ºC grew form I from hydroxy surfaces, and an 
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off-white crystal from perfluorinated surfaces.  When the off-white crystals were ground 
a day later it became a white powder and the diffraction pattern proved the powder to be 
form I.  Being wary of a possible transition to form I from another form, the high 
temperature experiments were repeated again, with the oven reading 90 ºC at the time the 
vials were left to crystallize.  As soon as all solvent had evaporated (approx 24 hours 
later), the off-white crystals which had again formed in the perfluorinated vial were 
ground and remained an off-white color.  The diffraction pattern did not match forms I or 
III, but had some key peaks reported from a literature powder diffraction pattern of form 
II.  The sample was left on the diffraction slide overnight, and approximately one day 
later appeared lighter in color.  Another diffraction pattern was taken of the same sample 
that had not been altered in any way, and matched the calculated pattern of form I.   
 
 
Ethanol solutions of flufenamic acid at room temperature (approx 20-25 ºC) grow 
exclusively form I (metastable) in vials with perfluorinated surfaces.  The same solution 
at the same temperature grows exclusively form III (stable) in vials with hydroxy 
surfaces.  These results are contrary to the previous results with indomethacin.  This may 
be tied into the fact that flufenamic acid is the only pharmaceutical we screened that did 
not stick to the sides of vials with hydroxy surfaces.  Fluorous surfaces and compounds 
are very xenophobic, which may explain why flufenamic acid does not stick to the sides 
of vials during crystallization.  The CF3 group may have more favorable interactions with 
the fluorous surface than the hydroxy surface, which would explain why we see the stable 
form in the hydroxy vials, and the metastable form in perfluorinated vials.  As seen from 
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the crystal structure in Fgure 17 form I has exposed CF3 groups along a major face which 
may be able to interact favorably with a similar surface.
24
   
 
The crystallization results from toluene were equally interesting.  It is known that form I 
is typically obtained by evaporation from non-polar solvents, so this may explain why 
only form I was seen at room temperature regardless of the vial used.  The appearance of 
what seemed to be form II at high temperatures in perfluorinated vials fits with the theory 
that interactions between CF3 groups of the compound and surface promote formation of 
the metastable form.  Above 104 ºC form II becomes the metastable form, and it is highly 
likely that the temperature in the region of the oven where crystallization occurred was 
above this temperature.  This was evidenced by apparent decomposition of flufenamic 
acid left at the bottom of the oven where the temperature was highest.  The vials that 
produced form II were on the first rack up from the bottom of the oven, while the 
thermometer was at the very top.  The oven is heated from the bottom, and it is fair to 
assume that the lower in the oven the vial is placed, the higher the temperature.  The oven 
temperature reading when the vials were added was 90 ºC, right after the door had been 
opened.  This also suggests that the average temperature of the oven was somewhat 
above this number.  As form II and form I are monotropic to each other, it makes sense 
that form II transformed to form I when left at room temperature for any significant 
amount of time.  This relationship was also shown by the fact that form II was not seen 
when forms I and III were simply left in the oven at high temperature after crystallizing 
out of solution.  We suspect the formation of exclusively form III from ethanol solutions 
at high temperatures was due to fast solvent evaporation.  Form III was metastable at 
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these temperatures, and probably crashed out of solution before having a chance to 
rearrange to the more stable form I.  Ethanol boils below the transition temperature when 
form II overtakes form III as the metastable form, so it is highly unlikely that form II 
would be stable enough to exist, and thus would not be seen in ethanol solution.   
 
 
NITROFURANTOIN 
 
Nitrofurantoin (Figure 21) is an antibiotic used to eliminate bacteria from the body in the 
treatment of some kinds of infections.
25
  Nitrofurantoin is an excellent pharmaceutical for 
these types of studies because it is known to exist in two anhydrous polymorphs (β and 
) as well as two monohydrates.   
 
Figure 18.  Structure of nitrofurantoin. 
 
 
We set up crystallizations of nitrofurantoin from acetone in vials with many different 
monolayers.  All vials were filled with the same nitrofurantoin stock solution, and kept 
under the same conditions.  This first set of crystallizations took place on a lab benchtop.  
The first results obtained appeared to be all of the same morphology.  Every vial 
contained thin yellow needles.  Upon closer inspection, it could be seen that in the 
perfluorinated vials underneath the yellow needles were very small red blocks.  Powder 
X-ray diffraction confirmed that the yellow needles were a monohydrate (we only 
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encountered one monohydrate through all experiments), and the red blocks produced a 
pattern similar to the  β form.  There was not a large amount of sample, so the pattern was 
difficult to confirm.  The experiment was repeated, this time using only perfluorinated 
vials and hydroxy vials.  These vials were left in the hood to crystallize to prevent any 
outside stimuli from affecting nucleation.  These crystallizations produced all red blocks 
in every vial regardless of SAM.  These red blocks were confirmed to be β by powder X-
ray diffraction as seen in figure 22.  Assuming the level of moisture was a contribution 
the experiments were repeated with a carefully prepared anhydrous solutions, as well as a 
solution containing approximately 5% water.  These crystallizations produced all red 
blocks from the anhydrous solution, and all yellow needles from the 5% water solution.  
Yellow needles were confirmed to be the monohydrate by both X-ray diffraction and 
DSC. 
 
 
Figure 19.  Diffraction pattern of β grown in perfluorinated vials (blue) vs. the 
calculated pattern (magenta). 
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Figure 20. Diffraction pattern of orange crystals grown in hydroxy vials. 
 
 
Figure 21. Diffraction pattern of thin yellow needles grown in hydroxy vials with 5% 
water solution 
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Figure 22. DSC data of yellow needles grown in hydroxy vials with 5% water solution 
showing loss of water well before decomposition. 
 
The anhydrous experiments were repeated again, and this time upon closer inspection a 
slight color change was seen between the perfluorinated vials and hydroxy vials.  Crystals 
growing on the sides of the hydroxy vials were a lighter orange in color, originally 
thought to be a different color because of smaller crystal size; it was observed under a 
microscope that the crystals themselves looked physically different from the ones formed 
in perfluorinated vials.  Many small vials were set up with perfluorinated and hydroxy 
surfaces and left at various locations.  All of the hydroxy vials shared the orange crystals, 
and perfluorinated vials showed mainly red crystals.  However, diffraction patterns still 
all matched β.  The orange crystals showed a few discrepancies with the calculated 
literature pattern, but did not show characteristic peaks of .   
 
30 300  (ºC) 
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Figure 23.  Red crystals of nitrofurantoin grown in PF vial and orange crystals grown 
in the hydroxy vial. 
 
 
Figure 24.  Images taken with a microscope camera.  Red crystals from PF vials can be 
seen on the left, yellow/orange crystals from hydroxy vials can be seen on the right. 
 
 
 
The appearance of the yellow needles indicates that the original solution used for 
crystallization may have been contaminated with water, or perhaps moisture in the 
atmosphere was high at that particular time.  We have no reason to believe that the 
original red blocks seen were another monohydrate, as their diffraction pattern was very 
similar to the calculated patter for the β form.  It is very interesting that the anhydrous 
form grew only in the perfluorinated vial, and was not seen on any other surface.  It is 
possible that the perfluorinated surface promotes formation of the anhydrous form, but as 
 27 
the results were not reproducible it is impossible to conclude this certainly.  What is more 
interesting was the presence of the red form in all of the perfluorinated vials thereafter, 
excluding the vials containing 5% water solution.  These crystals had a diffraction pattern 
matching that of the β form perfectly.  In the hydroxy vials, the orange crystals which 
appeared different under a microscope also produced a pattern similar to the calculated 
pattern.  There were small differences, but no hard evidence through X-ray diffraction to 
suggest that they were a different form.  The main reason another form is suspected is the 
shape and color differ from the crystals seen in perfluorinated vials.  We suspect that the 
red blocks are the more stable form, and that the orange crystals are transforming during 
grinding for powder diffraction.  This observation along with the fact that there were no 
crystals seen growing on the sides of the perfluorinated vials indicated that perfluorinated 
surfaces promote the more stable form.  We suspect that the metastable form grows on 
the sides of the hydroxyl vials at the solvent line, seeding the rest of the solution and 
promoting growth of the metastable form.  The perfluorinated vials allow for the stable 
form to grow over a longer period of time, and raise the nucleation barrier for the 
metastable form by inhibiting surface nucleation.  These findings match well with the 
previous results with indomethacin.   
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CONCLUSIONS 
 
All of our results indicate that there is something special about fluorous surfaces.  They 
have unique non-stick properties not exhibited by any other surface we used in these 
studies.  By inhibiting the growth of crystals at the solvent line, they often promote the 
growth of the more stable form.  The exception is flufenamic acid, which displays similar 
properties to the surface itself.  The drug would not stick to the walls of any vial 
regardless of surface, and the reverse results were observed: perfluorinated surfaces 
promoted the metastable form.  In the case of all drugs tested, fluorous surfaces provided 
fewer and larger crystals than hydroxy vials containing the exact same solution of 
pharmaceutical.  This new approach to selectively growing stable polymorphs by 
removing nucleation sites could be of immense use to the industry.  Fluorous surfaces 
could be used to grow high quality crystals for analysis as well as providing seed crystals 
for pharmaceutical manufacture.  Fluorous surfaces may also be used in the 
pharmaceutical industry to screen for thermodynamically stable polymorphs.   
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